key: cord-0840198-0a4diqgz
authors: Walser, Marcel; Rothenberger, Sylvia; Hurdiss, Daniel L.; Schlegel, Anja; Calabro, Valérie; Fontaine, Simon; Villemagne, Denis; Paladino, Maria; Hospodarsch, Tanja; Neculcea, Alexandra; Cornelius, Andreas; Schildknecht, Patricia; Matzner, Mirela; Hänggi, Martin; Franchini, Marco; Kaufmann, Yvonne; Schaible, Doris; Schlegel, Iris; Iss, Chloe; Looser, Thamar; Mangold, Susanne; Herzog, Christel; Schiegg, Dieter; Reichen, Christian; Radom, Filip; Bosshart, Andreas; Lehmann, Andreas; Haeuptle, Micha A.; Zürcher, Alexander; Vagt, Toni; Sigrist, Gabriel; Straumann, Marcel; Proba, Karl; Veitonmäki, Niina; Dawson, Keith M.; Zitt, Christof; Mayor, Jennifer; Ryter, Sarah; Lyoo, Heyrhyoung; Wang, Chunyan; Li, Wentao; Drulyte, Ieva; Du, Wenjuan; Binz, H. Kaspar; de Waal, Leon; Stittelaar, Koert J.; Taplin, Sarah; Lewis, Seth; Steiner, Daniel; van Kuppeveld, Frank J.M.; Engler, Olivier; Bosch, Berend-Jan; Stumpp, Michael T.; Amstutz, Patrick
title: Highly potent anti-SARS-CoV-2 multi-DARPin therapeutic candidates
date: 2020-11-20
journal: bioRxiv
DOI: 10.1101/2020.08.25.256339
sha: 0d0805fe7c5bd686a67fcada8b9ca968a93989f3
doc_id: 840198
cord_uid: 0a4diqgz

Globally accessible therapeutics against SARS-CoV-2 are urgently needed. Here, we report the generation of the first anti-SARS-CoV-2 DARPin molecules with therapeutic potential as well as rapid large-scale production capabilities. Highly potent multi-DARPin molecules with low picomolar virus neutralization efficacies were generated by molecular linkage of three different mono-DARPin molecules. These multi-DARPin molecules target various domains of the SARS-CoV-2 spike protein, thereby limiting possible viral escape. Cryo-EM analysis of individual mono-DARPin molecules provided structural explanations for the mode of action. Analysis of the protective efficacy of one multi-DARPin molecule in a hamster SARS-CoV-2 infection model demonstrated a significant reduction of pathogenesis. Taken together, the multi-DARPin molecules reported here, one of which is currently entering clinical studies, constitute promising therapeutics against the COVID-19 pandemic.

Fighting the COVID-19 pandemic will require coordinated global efforts to maximize the benefits of vaccinations and therapeutics(1). Even though vaccine and therapeutic development efforts have progressed considerably, there is, and will be, a remaining medical need for globally accessible therapeutics to treat patients and to protect health care workers, as well as individuals with underlying 5 medical conditions that preclude them from being vaccinated. Neutralizing monoclonal antibodies are expected to be critically important and could be readily available (2) (3) (4) , however they are complex to manufacture and come at a considerable cost. These logistical hurdles may severely limit accessibility, thus preventing an effective global solution (5) . 10 DARPin molecules are an emerging class of novel therapeutics that are actively being developed in ophthalmology and oncology, with four molecules at a clinical stage (6, 7) . Here, we report the generation and characterization of the first anti-viral DARPin molecules in the context of the COVID-19 pandemic. DARPin molecules contain naturally occurring ankyrin repeat motifs. To generate therapeutic DARPin molecules, a pure in vitro approach (i.e. selections via ribosome display) is possible 15 and can be carried out in a very short time frame, only requiring the target protein, in this case the SARS-CoV-2 spike protein or subdomains thereof. Hence, therapeutic DARPin molecules can be prepared independently of patient samples or animal immunizations. DARPin molecules can be monospecific or linked by peptide linkers to form single-chain multi-DARPin molecules with multiple specificities. Notably, DARPin molecules can be manufactured by microbial fermentation, and thus be 20 potentially available world-wide within a short time due to lower technical requirements to provide large-scale clinical grade material. Additionally, the high heat stability of DARPin molecules may offer the prospect of a reduced cold chain for distribution around the globe.

The SARS-CoV-2 spike protein (8, 9) , presented as a metastable prefusion trimer at the viral surface, 25 mediates virus entry into the host cell. The spike protein comprises multiple functional domains: S1, which includes the N-terminal domain (NTD) and the receptor binding domain (RBD) responsible for interaction with the angiotensin-converting enzyme 2 (ACE2) host receptor(1, 8, 10, 11) , and the S2 domain, which is responsible for virus-host cell membrane fusion via extensive, irreversible conformational changes (12) (13) (14) . This domain composition opens the possibility to target several sites 30 on a single viral protein, leading to multiple mechanisms of inhibition. Such a multi-pronged approach is expected to lead to higher potencies, lower doses, and better protection against potential viral escape mutations.

With antibody approaches focusing mostly on one or two epitopes of the SARS-CoV-2 spike protein, we present here a novel approach using DARPin molecules to simultaneously bind three sites on the trimeric SARS-CoV-2 spike protein. The results reported below describe the development and characterization of mono-specific DARPin molecules against distinct domains of the spike protein, the selection process for the most potent mono-DARPin molecules and, supported by cryo-EM data, their 5 rational combination into highly potent multi-DARPin molecules. Furthermore, we demonstrate the protective efficacy of a multi-DARPin molecule against virus replication and severe disease in a hamster model of COVID-19. We anticipate that antiviral multi-DARPin molecules have the potential to become an easy-to-deploy antiviral approach for treatment and/or prevention of COVID-19. Based on the results presented here, MP0420 or ensovibep -a derivative of MR-DC, is currently being studied in 10 clinical Phase 1.

The DARPin technology is based on naïve DARPin libraries (6) , with a physical diversity of about 10 12 5 different mono-DARPin molecules, allowing the selection of sets of very diverse binding molecules by ribosome display (15, 16) , the method of choice when dealing with libraries of such large diversities.

DARPin libraries are based on a consensus design approach using hundreds of ankyrin repeat protein sequences of the human and mouse genome (17) . An overview of the entire generation process of anti-SARS-CoV-2 spike protein binding DARPin molecules is shown in Figure 1 . To obtain individual DARPin 10 molecules binding to distinct domains of the SARS-CoV-2 spike protein and potentially inhibiting viral cell entry, we focused on generating DARPin molecules binding to the receptor binding domain (RBD), the S1 N-terminal domain (NTD) or the S2 domain (18) . After four ribosome display selection rounds ( Figure 1A ), we further enriched for the most potently binding DARPin molecules through screening of 3'420 E. coli cell extracts overexpressing individual DARPin molecules by homogeneous time-resolved 15 fluorescence (HTRF) assays for binding to different spike protein domains ( Figure 1B ). Based on binding and ACE2 inhibition profiles obtained in HTRF, which allowed mapping of mono-DARPin molecules to different spike domains, 380 DARPin molecules were selected to be expressed in 96-well format and purified to homogeneity. DARPin molecules were further characterized for antiviral potency in a VSVpseudovirion neutralization assay (PsV NA) as well as biophysically by size exclusion chromatography 20 (SEC), Sypro-Orange thermal stability assessment (19) , ProteOn surface plasmon resonance (SPR) target affinity assessment, and ELISA, to orthogonally evaluate target binding ( Figure 1C and D). In parallel to the characterization of the 380 mono-DARPin molecules, 6 mono-DARPin molecules of known spike domain specificity were used to randomly assemble a set of 192 tri-specific DARPin molecules ( Figure 1E ). The antiviral potencies, determined in a PsV-NA screening assay, of these 25 randomly combined tri-specific DARPin molecules provided valuable information on the most potent tri-specific combinations and formats. Based on the combined data for the 380 mono-DARPin molecules, 11 of them with low pM to low nM affinities, excellent biophysical properties, diversities in amino acid sequences as well as binding for various SARS-CoV-2 spike protein domains (Supplementary   Table 1 and Supplementary Figure 1) were selected for the rational generation of 22 multi-DARPin 30 molecules described below ( Figure 1F ). After detailed characterization of these 22 multi-DARPin candidates, systemic exposure was assessed in mice and in Syrian golden hamsters for the most promising multi-DARPin candidates ( Figure 1G ). The multi-DARPin candidate with the longer systemic half-life was evaluated for SARS-CoV-2 protection in a Covid-19 Syrian golden hamster model ( Figure   1H ). 35

We aimed to increase virus neutralizing potency through molecular linkage of mono-DARPin molecules. Using the 11 selected mono-specific DARPin molecules, a total of 22 multi-DARPin molecules were generated and characterized in detail, each comprising 3 mono-DARPin molecules 5 against various epitopes of the spike protein as well as two mono-DARPin molecules binding to human serum albumin (HSA), which have been previously shown to confer long half-life to other DARPin molecules in animals and humans(7) (Supplementary Table 2 ). Each of the 22 multi-DARPin molecules contained at least one RBD-binding domain since preventing ACE2 receptor interaction is assumed to be the strongest point of interference with virus entering the host cell. Multi-DARPin molecules were 10 designed to contain several binding modules to RBD (multi-RBD DARPin molecules) or to several distinct domains (multi-mode DARPin molecules). Based on profiling of 22 multi-DARPin molecules for their biophysical properties and antiviral potency (Supplementary Table 2 sequencing of the individual mono-DARPin components of MR-DC revealed a similar, but not identical, arrangement of amino acids, suggesting that they share a common mechanism of binding to the RBD.

In contrast, the individual components of MM-DC exhibited a high level of sequence diversity, consistent with their different targeting mechanisms (Figure 2c ). Neutralization potency for MR-DC and MM-DC was 56 and 36-fold higher in PsV NA, respectively, relative to the most potent neutralizing 20 individual mono-DARPin that was used for the design of the two types of multi-DARPin molecules (Figure 2d-e). In addition, IC50 values for potency determination in a VSV-SARS-CoV2 pseudotype neutralization assay for MR-DC and MM-DC was similar or superior to that of three earlier described potent neutralizing antibodies (20, 21) . Neutralization assays with the infectious SARS-CoV-2 yielded IC50 values of 12 pM for MR-DC (1 ng/ml) and 80 pM for MM-DC (7 ng/ml), respectively (Figure 2f). In 25 addition, both multi-DARPin molecules could effectively neutralize pseudotype viruses carrying spike proteins containing natural occurring polymorphisms, including the frequently occurring D614G mutation (Supplementary Table 3 ). The extremely high neutralization potencies are key for SARS-CoV-2 treatment in particular in a prophylactic setting where very low virus titers at the beginning of the infection are expected. 30

To gain further insights into the mode of inhibition and binding, three individual mono-DARPin molecules targeting RBD, S1-NTD, or S2, were subjected to cryo-electron microscopy (cryo-EM) analysis in complex with the trimeric spike ectodomain. In each case, few intact spikes remained 35 following incubation with the mono-DARPin molecules, particularly with the S2 binder (Supplementary Figures 3b and 4) . These results demonstrate that mono-DARPin 10 #3 binding prevents closure of the RBD through a previously described ratcheting mechanism (18) . (Figure 3d ). This mono-DARPin molecule binds to the most distal region of the NTD, which is not resolved in the majority of available spike structures (13, 23) . However, several spike structures with nearly completely modelled 35

NTDs were recently reported (24, 25) . The better resolved NTD loops in these structures allowed us to further narrow down the DARPin epitope, indicating that the concave binding surface is ideally situated to interact with the N5 loop, encompassing residues 246-258 (26) (Figure 3e) . A recently described monoclonal antibody, 4A8 (26) , also targets the NTD, involving an extensive hydrophilic interaction network with the N3 loop and, to a lesser extent, the N5 loop. In contrast, molecular docking 5 experiments suggest mono-DARPin molecule #9 interacts with the NTD primarily with N5 loop residues 248-252 (Supplementary Figure 7) , with an interface area of ~600 Å 2 and involving both hydrophilic and hydrophobic interactions. Based on our cryo-EM structures, molecular modelling was used to demonstrate that a linker, used in the multi-DARPin format, would permit simultaneous binding of the NTD and RBD-targeting mono-DARPin molecules (Figure 3f ). 10

Cumulatively, our structural analysis allowed us to generate models of the MR-DC and MM-DC molecules in contact with the spike protein using 3D molecular modeling tools (Supplementary Figure   8 ). In both cases, the half-life extension modules have sufficient space to bind HSA. Within the distance limited by the linker length, we identified a potential binding site for the S2 binder, suggesting that simultaneous binding to the spike protein is feasible. However, structural analysis of S ectodomains 15 incubated with the S2 binder #10 did not reveal any unambiguous density for the bound mono-DARPin.

The low number of intact ectodomains remaining after incubation with mono-DARPin #10 suggests that, compared to mono-DARPin molecules #3 and #9, the S2 binder has the greatest destabilizing effect on the structural integrity of the S ectodomains (Supplementary Figure 2 ).

In order to assess the in vivo antiviral efficacy of our multi-DARPin molecule MR-DC, a hamster Covid-19 disease model was performed to study the potential for preventing SARS-CoV-2 related disease The most potent neutralizing mono-DARPin molecules were found to target the RBD, blocking the spike-ACE2 interaction necessary for infection. This finding is congruent with the identified epitopes of potent neutralizing antibodies obtained from COVID-19 patients (20, (35) (36) (37) (38) (39) . Thus, the in vitro approach using DARPin molecules independently confirms that the ACE2 interaction site on the 20 SARS-CoV-2 spike protein is one of the most vulnerable sites to block virus infection in cell culture.

The single-chain binding domain nature of DARPin molecules facilitated the design of multiparatopic and multispecific DARPin molecules with greatly increased neutralization potencies.

Virus neutralization capacity increased substantially when three DARPin molecules were linkedrelative to the individual modules -likely due to both, increased avidity when binding to the trimeric 25 spike proteins as well as multiple spike domains. A similar strategy with comparable outcome has been recently described for nanobodies (31) . The observed neutralization capacity of the multi-DARPin molecules in the low picomolar range is similar to or even outcompetes the neutralizing capacities of Although it remains to be determined if additional mutations will impact the neutralization potencies of the multi-DARPin molecules, we expect Multi-DARPin molecules to keep high potency in case the SARS-CoV-2 spike protein should mutate in the future, especially when multiple domains are addressed.

DARPin molecules (30) have shown good promise for both ophthalmology and oncology patients. Within oncology, MP0250 is the DARPin molecule (7) with most data available to date:

MP0250 is a dual inhibitor of VEGF and HGF and is being developed for multiple myeloma in 5 combination with small molecules. MP0250 shows a long systemic half-life of about 2 weeks in human, low immunogenicity potential, and has been given to individual patients for more than two years. All Due to the lack of an immune stimulating Fc-fragment, we envision no generation of antibody dependent enhancement (ADE) effects, a potential additive risk of monoclonal antibodies discussed for patients with inflamed lungs (40) (41) (42) (43) . Thus, the multi-DARPin molecules represent very attractive 15 potential therapeutics for clinical studies.

Generally, DARPin molecules demonstrate excellent temperature stability and can be easily produced in bacterial expression systems at very high yields allowing cost-effective and scalable production of antiviral biologicals at industrial quantities (supplementary table 5 ). Consequently, global access to this novel class of therapeutics may be highly additive to monoclonal antibody approaches and thus 20 contribute to overcoming the COVID-19 pandemic (44) .

We anticipate that the presented workflow for DARPin development can be applied for any future emerging (corona)virus. We have proven that high-affinity binding and potently neutralizing DARPin molecules can be developed in a matter of weeks, without the requirement of immunization of animals or access to patient materials. Such fast track development strategies of picomolar 25

inhibitors are critical to raise preparedness level towards novel pandemic viruses.

The EM density maps for the SARS-CoV-2 spike ectodomain in complex with mono-DARPin #3 (state 1 and state 2), and mono-DARPin #9 have been deposited to the Electron Microscopy Data Bank under 30 the accession codes EMD-11953, EMD-11954 and EMD-11956, respectively. The mono-DARPin and multi-DARPin sequences, and pseudo-atomic models derived from molecular docking experiments, are available (by contacting the corresponding author) for research purposes only under an MTA, which allows the use of the data for non-commercial purposes but not their disclosure to third parties.

We would particularly like to thank those colleagues at Molecular Partners who are not included in the author list and are currently advancing the program through the clinic. Additionally, we would like to shown in a rainbow color scheme from the N terminus (blue) to the C terminus (red). nasal turbinate (f) and significant reduction of viral loads in the lung at 1600 µg, with two animals below detection limit, as well as trend to dose-dependent reduction of viral loads at 160 µg (g). Statistically significant differences between Placebo and 1600 µg group: *T-test; P value = 0.0183 / **T-test; P value = 0.0031.

Walser et al.

Proteins used for selections comprised SARS-CoV-2 S protein ectodomain (SARS2-Secto-d72-GCN4-Streptag; University of Utrecht), SARS-CoV-2 S protein (S1+S2 ECT, His-tag; Sinobiological 40589-V08B1), Bio-COVID-19_S1 protein_His_Avitag (Acro Biosystems), SARS2-S1-Flag-3Streptag (University of Utrecht), COVID-19_S_protein_RBD_Fc (Acro Biosystems), and SARS2-S1B-2Streptag (University of Utrecht). Proteins were biotinylated by using standard methods.

DARPin libraries(6) (N2C and N3C) were used in ribosome display selections (15, 16) against the SARS-CoV-2 spike protein fragments. Four selection rounds were performed per target and per library using decreasing target concentrations and increasing washing stringency to increase selection pressure from round 1 to round 4. The number of reverse transcription (RT)-PCR cycles after each selection round was continuously reduced, adjusting to the selection yield due to enrichment of binders. The 12 resulting pools were then subjected to a binder screening.

Mono-DARPin molecules specifically binding to the S1-RBD, S1-NTD and S2 domains of the spike France) to a well of a 384-well plate and incubated for 120 min at 4°C. The HTRF was read-out on a Tecan M1000 using a 340 nm excitation wavelength and a 620±10 nm emission filter for background fluorescence detection and a 665±10 nm emission filter to detect the fluorescence signal for specific binding. The extract of each lysed clone was tested for binding to the biotinylated spike protein domains, in order to assess specific binding to the spike protein.

Multi-DARPin molecules were prepared using Gibson assembly as described (45) . The individual domains are linked with proline-threonine-rich polypeptide linkers (45) .

DARPin molecules were expressed in E. coli and purified as described (45) . Characterization of mono-DARPin molecules included SDS-PAGE, size exclusion chromatography, surface plasmon resonance, SARS-CoV-2 pseudotype virus inhibition assay, as well as live virus inhibition assay. Characterization of multi-DARPin molecules included SDS-PAGE (fully intact size without degradation; not shown), mass spectrometry (expected molecular weight; not shown), size exclusion chromatography coupled to static light scattering, circular dichroism, storage stability (stable at 60°C for 1 week; data not shown), serum stability (stable at 37°C in serum for one week; data not shown), surface plasmon resonance, SARS-CoV-2 pseudotype virus inhibition assay, live virus inhibition assay, hamster pharmacokinetic analysis, and hamster efficacy model as further described below.

Circular dichroism measurement was performed with a Jasco J-815 using a 1 cm pathlength cuvette (Hellma) with the monitor sensor inserted in the cuvette. The MRE at 222 nm was followed over a temperature ramp from 20°C to 90°C (heating and cooling). Spectra from 190-250 nm were taken before and after the variable temperature measurement at 20°C. The protein was measured at 0.25 M in PBS.

SPR assays were used to determine the binding affinity of mono-DARPin as well as multi-DARPin molecules to the spike protein of SARS-CoV-2. All SPR data were generated using a Bio-Rad ProteOn XPR36 instrument with PBS-T (0.005% Tween20) as running buffer. A new neutravidin sensor chip (NLC) was air-initialized and conditioned according to Bio-Rad manual.

Biologics) was captured to ~3400 RUs (30 μg/ml, 30 μl/min, 300 s). Two buffer injections (100 μl/min, 60 s) followed by two 12.5 mM NaOH regeneration steps (100 μl/min, 18 s) were applied before the first injections. Mono-domain DARPin proteins were injected (at 50/16.7/5.6/1.9/0.6 nM) for 180 s at 100 μl/min for association and dissociation was recorded for 3600 s (at 100 μl/min). The ligand was regenerated with a 12.5 mM NaOH pulse (100 μl/min, 18 s). The data was double referenced against the empty surface and a buffer injection and fitted according to the 1:1 Langmuir model.

Multi-DARPin molecules: Chemically biotinylated (via lysines) COVID-19_S_protein_RBD_Fc (Acro Biosystems) was captured to ~1000 RUs (775 ng/ml, 30 μl/min, 300 s). Two buffer injections (100 μl/min, 60s) followed by two 12.5 mM NaOH regeneration steps (100 μl/min, 18s) were applied before the first injections. One single concentration of 25 nM of each multi-domain drug candidate was injected for 180 s at 100 μl/min for association and dissociation was recorded for 36'000 s (at 100 μl/min). The data was double referenced against the empty surface and a buffer injection. Due to avidity gain, no significant dissociation could be recorded during the measured time. Luminescence was read after 2 minutes shaking on an orbital shaker and 10 min incubation at RT using the GloMax instrument (Promega, Madison, USA).

SARS-CoV-2 pseudoviruses were generated as described previously (46) . Cryo-electron microscopy 4 μl of purified S ectodomain (9 μM) was mixed with 1 μl of 50 μM mono-DAPRin #3, #9 or #10, and incubated for 15 seconds at room temperature. 3 μl of sample was then dispensed on Quantifoil R1.2/1.3 200-mesh grids (Quantifoil Micro Tools GmbH) that had been freshly glow discharged for 30 s at 20 mA. Grids were blotted using blot force +2, for 5 s using Whatman No. 1 filter paper and immediately plunge-frozen into liquid ethane cooled by liquid nitrogen using a Vitrobot Mark IV plunger (Thermo Fisher Scientific) equilibrated to ~95% relative humidity, 4°C. Movies of frozenhydrated specimens were collected using Glacios Cryo-TEM (Thermo Fisher Scientific) operating at 200 keV and equipped with a Falcon 4 Direct Electron Detector (Thermo Fisher Scientific). For additional analysis of mono-DARPin #3, 4 μl of purified S ectodomain (18 μM) was mixed with 1 μl of 100 μM DARPin, and incubated for 60 s at room temperature. Grids were prepared as described above, and movies were collected using a Titan Krios Cryo-TEM (Thermo Fisher Scientific) operating at 300 keV and equipped with a Falcon 4 Direct Electron Detector (Thermo Fisher Scientific). All cryo-EM data were acquired using the EPU 2 software (Thermo Fisher Scientific) with a 30-degree stage tilt to account for preferred orientation of the samples. Movies were collected in electron counting mode at 92,000x (Glacios) or 75,000x (Titan Krios), corresponding to a pixel size of 1.1 Å/pix over a defocus range of -1.25 to -2.5 μm.

Movie stacks were manually inspected and then imported in Relion version 3.0.1 (48) . Drift and gain correction were performed with MotionCor2(49), and GCTF(50) was used to estimate the contrast transfer function for each movie. Particles were automatically picked using a gaussian blob template and Fourier binned (2 x 2) particles were extracted and subjected to two rounds of 2D classification, ignoring CTFs until the first peak. Particles selected from 2D classification were subject to a single round of 3D classification. Particles belonging to the best classes were re-extracted unbinned, 3D autorefined and post-processed. Iterative rounds of per particle defocus estimation, 3D auto-refinement and post-processing were used to account for the 30-degree stage tilt used during data collection. An overview of the image processing workflows for each of the mono-DARPin samples is shown in supplementary Figure 2 .

Homology models of mono-DARPin molecules #3 and #9 were generated with Rosetta(51). The consensus designed ankyrin repeat domain PDB ID:2xee was used as template. Mutations were introduced with RosettaRemodel(52) with fixed backbone, and the structure was refined with RosettaRelax (53) . Forty refined structures were clustered using RosettaCluster with 0.3 Å radius, and the lowest-energy model from the largest cluster served as the final model. These models were then used for fitting domain #3 and #9 into the observed electron density generated from the complex structure of the spike protein.

To facilitate accurate fitting of the DARPin coordinates into their respective cryo-EM maps, difference density maps of the bound DARPin molecules were produced as described previously (54) . In a last step, the models of mono-DARPin #3:RBD (residues 303-526) and mono-DARPin #9:NTD (residues 14-303) were refined with Rosetta. The structures were pre-relaxed for docking and served as input for local, high-resolution docking with RosettaDock(55) with fixed backbone. Five hundred models were generated and clustered with 1 Å radius (RosettaCluster). Two largest clusters were inspected and the lowest-energy model from more conserved group (i.e., with lower rigid-body perturbation from the input structure) was taken further for additional all-atom refinement with RosettaRelax(53), with protocol optimized for interfaces (InterfaceRelax2019). Fifty models were generated, and the lowest scoring model was selected. This model was used to describe the 

The study was performed at Viroclinics Xplore, Schaijk, The Netherlands.

SARS-CoV-2 isolate BetaCoV/Munich/BavPat1/2020 was kindly provided by Prof. Dr. C. Drosten (European Virus Archive Global # 026V-03883). With a history of 1 passage in Vero-TMPRSS2 and 3 passages in Vero E6 cells (ATCC), the seed stock was titrated in Vero E6 cells to a concentration of 7.1 log10 TCID50/ml. The seed stock was thawed and diluted in cold phosphate-buffered saline (PBS) prior to infection.

Twenty-four specific-pathogen-free (SPF) 15 weeks-old Syrian golden hamsters (Mesocricetus auratus, females and males, approximate body weights of 160g, provided by Envigo) were uniquely identified using individually-coded animal markers. They were housed in elongated type 2 group cages with two animals per cage under BSL-III conditions during the experiment. They were kept according to the standards of Dutch law for animal experimentation and were checked daily for overt signs of disease. The study was carried out following approval by an independent animal welfare body (approval AVD277002015283-WP13) and complied with all relevant ethical regulations for animal testing.

Four groups of six hamsters were treated with multi-DARPin molecule MR-DC via the intraperitoneal route with 16 µg, 160 µg, or 1600 µg doses per animal or with a placebo 24 hours prior to infection and subsequently animals were inoculated intra-nasally with 100 µL PBS containing 5x10 4 TCID50 SARS-CoV-2. The inoculum was instilled dropwise using a pipette and equally divided over both nostrils. The animals were weighed regularly and throat swabs, for quantitative PCR and infectious virus titration, were collected on a daily basis. For all animal procedures, the animals were sedated with isoflurane (3-4%/O2).

Upon necropsy at day 4 post infection, full-body gross pathology was performed for each animal and all abnormalities recorded and described. All lung lobes were inspected, and the percentage of affected lung tissue was estimated by eye. Samples of the left nasal turbinates, trachea and the entire left lung (often with presence of the primary bronchi) were preserved in 10% neutral buffered formalin for histopathology. Samples of the right lung parenchyma and right nasal turbinates were frozen for quantitative PCR and virus titration.

Throat swabs and homogenized tissue samples (lungs and nasal turbinates) were thawed and tested for the presence of SARS-CoV-2 infectious virus using virus titration. To this end, quadruplicate 10-fold serial dilutions were used to determine the virus titers on confluent layers of Vero E6 cells. Serial dilutions of the samples (throat swabs and tissue homogenates) were prepared and incubated on Vero E6 monolayers for 1 hour at 37°C. Vero E6 monolayers were washed and incubated with infection medium for 4-6 days at 37°C after which plates were scored for cytopathogenic effect (CPE) using the vitality marker WST-8. Viral titers (TCID50) were calculated using the method of Spearman-Karber.

Samples of tissue from the respiratory tract (lung, trachea, and nasal turbinates) and lymphoid organs (spleen and mandibular lymph node) were fixed in 10% neutral buffered formalin (24-48h) and embedded in paraffin. Tissue sections were then stained with hematoxylin and eosin and examined by light microscopy. A semi-quantitative histopathological analysis was performed, and findings scored using the following grades: absent (grade 0), minimal (grade 1), mild (grade 2), moderate (grade 3) or marked (grade 4). The average score for the dose groups was calculated for each finding in the respiratory tract ( Figure 4b ) and lymphoid organs (Figure 4c ).

Single-dose intraperitoneally administered dose pharmacokinetic measurements in female hamsters 

Supplementary 

A pneumonia outbreak associated with a new coronavirus of probable bat origin

The effect of large-scale anti-contagion policies on the COVID-19 pandemic

Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe

Rapid repurposing of drugs for COVID-19

Antibody therapies could be a bridge to a coronavirus vaccine -but will the world benefit?

High-affinity binders selected from designed ankyrin repeat protein libraries

First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors

Structural basis of receptor recognition by SARS-CoV-2

Structural insights into coronavirus entry

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Cryo-electron microscopy structure of a coronavirus spike glycoprotein trimer

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Tectonic conformational changes of a coronavirus spike glycoprotein promote membrane fusion

Ribosome display: selecting and evolving proteins in vitro that specifically bind to a target

Ribosome display efficiently selects and evolves high-affinity antibodies in vitro from immune libraries

Designing repeat proteins: well-expressed, soluble and stable proteins from combinatorial libraries of consensus ankyrin repeat proteins

Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion

The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability

Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody

Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

SARS-CoV-2 and bat RaTG13 spike glycoprotein structures inform on virus evolution and furin-cleavage effects

Distinct conformational states of SARS-CoV-2 spike protein

A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2

REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection. bioRxiv

Beyond Antibodies: The DARPin((R)) Drug Platform

An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike

De novo design of picomolar SARS-CoV-2 miniprotein inhibitors

De novo design of potent and resilient hACE2 decoys to neutralize SARS-CoV-2

Highly potent bispecific sybodies neutralize SARS-CoV-2. bioRxiv

Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2

Potently neutralizing and protective human antibodies against SARS-CoV-2

Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection

A perspective on potential antibody-dependent enhancement of SARS-CoV-2

Fruitful Neutralizing Antibody Pipeline Brings Hope To Defeat SARS-Cov-2

Dissecting antibody-mediated protection against SARS-CoV-2

The race to make COVID antibody therapies cheaper and more potent

Design and characterization of MP0250, a tri-specific anti-HGF/anti-VEGF DARPin(R) drug candidate

Macropinocytosis contributes to hantavirus entry into human airway epithelial cells

A human monoclonal antibody blocking SARS-CoV-2 infection

New tools for automated high-resolution cryo-EM structure determination in RELION-3

MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy

Gctf: Real-time CTF determination and correction

ROSETTA3: an object-oriented software suite for the simulation and design of macromolecules

RosettaRemodel: a generalized framework for flexible backbone protein design

A Pareto-optimal refinement method for protein design scaffolds

Cryo-EM structure of coronavirus-HKU1 haemagglutinin esterase reveals architectural changes arising from prolonged circulation in humans

Benchmarking and analysis of protein docking performance in Rosetta v3.2

LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions

UCSF Chimera--a visualization system for exploratory research and analysis

LigPlot+: multiple ligand-protein interaction diagrams for drug discovery